Primary Hyperoxaluria Type 1Symptoms, Doctors, Treatments, Advances & More
Primary Hyperoxaluria Type 1 Overview
Learn About Primary Hyperoxaluria Type 1
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Pierre Cochat practices practicing medicine in Bron, France. Mr. Cochat is rated as an Elite expert by MediFind in the treatment of Primary Hyperoxaluria Type 1. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Primary Hyperoxaluria, Nephrocalcinosis, Primary Hyperoxaluria Type 1, Kidney Transplant, and Liver Transplant.
Mayo Clinic-Rochester
John Lieske is a Nephrologist practicing medicine in Rochester, Minnesota. Dr. Lieske is rated as an Elite provider by MediFind in the treatment of Primary Hyperoxaluria Type 1. He is also highly rated in 23 other conditions, according to our data. His clinical expertise encompasses Kidney Stones, Nephrocalcinosis, Primary Hyperoxaluria, Kidney Transplant, and Lithotripsy.
Yaacov Frishberg practices practicing medicine in Jerusalem, Israel. Mr. Frishberg is rated as an Elite expert by MediFind in the treatment of Primary Hyperoxaluria Type 1. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Primary Hyperoxaluria Type 1, Primary Hyperoxaluria, Nephrocalcinosis, Calcinosis, and Kidney Transplant.
Summary: The goal of the redePHine study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ABO-101 in participants with primary hyperoxaluria type 1 (PH1). The trial will consist of 2 Study Periods. During the first Study Period, there will be 2 parts. In Part A, adult participants will be treated with a single ascending dose to identify a recommended dose. In Part B, pedia...
Summary: The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.
